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Abstract
Background
The iDSI reference case, originally published in 2014, aims to improve the quality and com-
parability of cost-effectiveness analyses (CEA). This study assesses whether the develop-
ment of the guideline is associated with an improvement in methodological and reporting
practices for CEAs using disability-adjusted life-years (DALYs).
Methods
We analyzed the Tufts Medical Center Global Health CEA Registry to identify cost-per-
DALY averted studies published from 2011 to 2017. Among each of 11 principles in the iDSI
reference case, we translated all methodological specifications and reporting standards into
a series of binary questions (satisfied or not satisfied) and awarded articles one point for
each item satisfied. We then calculated methodological and reporting adherence scores
separately as a percentage of total possible points, measured as normalized adherence
score (0% = no adherence; 100% = full adherence). Using the year 2014 as the dissemina-
tion period, we conducted a pre-post analysis. We also conducted sensitivity analyses
using: 1) optional criteria in scoring, 2) alternate dissemination period (2014–2015), and 3)
alternative comparator classification.
Results
Articles averaged 60% adherence to methodological specifications and 74% adherence to
reporting standards. While methodological adherence scores did not significantly improve
(59% pre-2014 vs. 60% post-2014, p = 0.53), reporting adherence scores increased slightly
over time (72% pre-2014 vs. 75% post-2014, p0.01). Overall, reporting adherence scores
exceeded methodological adherence scores (74% vs. 60%, p0.001). Articles seldom
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addressed budget impact (9% reporting, 10% methodological) or equity (7% reporting, 7%
methodological).
Conclusions
The iDSI reference case has substantial potential to serve as a useful resource for research-
ers and policy-makers in global health settings, but greater effort to promote adherence and
awareness is needed to achieve its potential.
Background
Policy makers and program managers, particularly those in low- and middle-income countries
(LMIC), often face prioritization decisions with limited resources [1]. Economic evaluation,
such as cost-effectiveness analyses (CEA), can provide insight into the comparative value of
various health interventions and therefore help inform priority setting [2].
Since the original Panel on Cost-Effectiveness in Health and Medicine proposed the use of
a reference case as a benchmark of quality and methodological rigor [3, 4], various guidelines
for conducting economic evaluation have been proposed [5, 6]. The Consolidated Health Eco-
nomic Evaluation Reporting Standards (CHEERS) Checklist, a widely cited reporting guide-
line, is used to ensure study results are reported with clarity and accuracy, yet does not provide
methodological guidelines for how analyses should be conducted [7]. Many countries, particu-
larly high-income ones, have also developed their own reference cases to inform decision-
making in their health care systems [8–11].
In contrast, most low- and middle-income countries (LMICs) have not developed such
guidelines, possibly due to their limited capacity to do so [12]. In fact, only 12 LMICs currently
have economic evaluation guidelines specific to their country [13]. Although the general prin-
ciples of guidelines for high-income countries can still be applied to LMICs, variations in both
approaches and methods used limit their usefulness. For example, most high-income country
guidelines suggest health outcomes be measured using quality-adjusted life-years (QALYs).
The estimation of QALYs requires a preference weight for different health states, called health-
related quality of life, on which LMICs often have limited data.
To address the need for a reference case that could broadly apply to different contexts, par-
ticularly in LMICs, the Bill and Melinda Gates Foundation (BMGF) supported the develop-
ment of the Gates Reference Case to ensure high quality and transparent CEA in global health
priority setting [14]. One of the key recommendations is to support the use of disability-
adjusted life years (DALY), as disability weights are more readily available and more easily
transferable across different countries [15]. The first version was published in 2014 as the
Gates Reference Case and, later in 2016, was renamed the International Decision Support Ini-
tiative (iDSI) Reference Case to convey the breadth of its intended applicability [14, 16].
The iDSI reference case fills a major gap in global health economics, as it is the only
resource of economic evaluation best practices for many policymakers in LMICs looking for
guidance on resource prioritization. However, no study has assessed whether the development
of the guideline is associated with an improvement in research practice for CEAs employing
DALYs. This paper aims to quantify the methodological and reporting quality of cost-per-
DALY averted studies over time, as measured by adherence to best practices enumerated by
the iDSI reference case.
CEA adherence to the iDSI reference case
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Methods
Data
The iDSI reference case. The iDSI reference case includes 11 principles: transparency,
comparator, evidence, measures of health outcome, costs, time horizon/discount rate, perspec-
tive, heterogeneity, uncertainty, budget impact, and equity considerations. Each principle has
a number of corresponding methodological specifications and reporting standards. By using
this tiered structure, the reference case aims to serve as a framework that provides best practice
guidance while allowing for flexibility depending on context [16], and thus is the most appro-
priate economic evaluation guideline for LMICs without their own national guidelines.
Global health CEA registry. We analyzed data from the Tufts Medical Center Global
Health CEA Registry, a continually updated database of English-language economic evalua-
tions in the form of cost-per-DALYs averted [17]. Among 620 cost-per-DALY averted studies
in the database, we selected all articles published three years before and after the initial release
of the iDSI reference case (2011–2017) to examine the impact of its publication on the litera-
ture (N = 398). We focused particularly on economic evaluations using the DALY metric
because it is recommended as a main outcome metric by the iDSI reference case and it is used
more often as a health outcome measure in LMICs than equivalent metrics such as the QALY
[16, 18].
To ensure a comprehensive assessment of adherence to the reference case, two independent
readers (JE and AP) extracted additional information from each study in our sample using
REDCap, an online data collection platform [19], including data on: currency reported; sub-
group analyses conducted; limitations reported; structural sensitivity analyses conducted; bud-
get impact conducted; justification of alternative methodology; and comparator setting.
Adherence score
We first translated all 30 methodological specifications and 38 reporting standards (across 11
principles) listed in the reference case into questions with discrete binary outcomes (standard
satisfied or standard not satisfied) (Table 1). We then designated reference case elements as
“required” or “optional” based on our interpretation of the language in the report (Table A in
S1 File). We deemed 19 methodological specifications and 21 reporting standards “required”.
Our base-case analysis examined adherence scores consisted only of “required” elements.
We evaluated each published cost-per-DALY averted study’s adherence to methodological
specifications (0–19 items) and reporting standards (0–21 items). We then separately calcu-
lated reporting and methods raw scores as a percentage of total possible points, measured as
normalized adherence score (0% = no adherence, i.e., no requirements adhered to; 100% = full
adherence, all requirements adhered to).
Analysis
Descriptive analysis. We examined the association between adherence score and certain
study characteristics, including whether the study cited the reference case, the study funder
characteristics, and journal attributes. We categorized study funders into the following groups
(not mutually exclusive): academic, government, healthcare organization, industry, intergov-
ernmental organization, BMGF, non-BMGF, and other. We also stratified selected articles into
clinical versus non-clinical journals using SCImago Journal Rank’s subject categorization
(medicine vs. health policy, public health, non-health) [20]. Finally, we recorded 2016 journal
impact factor quartiles and categorized studies as high impact (first quartile), medium impact
(second quartile), or low-impact (third and fourth quartiles) [20].
CEA adherence to the iDSI reference case
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Table 1. Evaluation criteria for adherence to the iDSI reference case.
Reference case
principle
Methodological specification evaluation question Reporting standard evaluation question
Transparency Decision problem, limitations, and
declarations of interest are appropriately
characterized.
Decision problem
characterized?
Decision problem (population,
intervention, comparator, outcome),
evaluation’s limitations, and declarations
of interest are fully described.
Population stated?
Limitations characterized? Intervention stated?
Declaration of interest
reported?
Comparator stated?
Outcome stated?
Limitations stated
(general)?
Conflict of interest
statement included?
Funding source stated?
Comparator(s) Intervention(s) currently offered to the
population (standard of care) is the base case
comparator.
Comparator is standard of
care?
Comparator and its availability are clearly
stated, and outcomes reported in
incremental cost effectiveness ratio.
Comparator clearly
stated?
Reported ICER?
Evidence Systematic literature review is used as source
of evidence.
Systematic review used? Methods of evidence collection are stated
and sources of parameters are cited.
Parameter sources
stated?
Parameter sources
cited?
Measure of health
outcome
DALYs are used as the base case outcome
measure.
DALYs as main outcome? Methods for weighting of DALYs are
stated.
Weighting methods
stated?
Costs Costs are relevant to the context and stated
perspective, and include implementation
costs.
Costs are true to reported
perspective?
Costs are reported in local currency and
USD.
Costs in local currency?
Costs include
implementation?
Costs in USD?
Time horizon and
discount rate
Lifetime time horizon and 3% discount rate
for costs and outcomes are used in base case.
Lifetime time horizon used? Time horizon and discount rate are
clearly stated.
Time horizon clearly
stated?
3% discount rate used? Discounting for both
costs and outcomes
clearly stated?
Discount rate used for costs
and effects?
Perspective Societal perspective is used in base case, and
relevant costs to this perspective (including
direct health costs) are included.
Limited societal perspective
used?
Perspective and base case outcomes are
clearly stated.
Perspective clearly
stated?
Direct health costs
reported?
Heterogeneity Heterogeneity is analyzed for appropriate
subgroups.
Subgroup analysis
performed/stated?
Subgroup characteristics and analysis of
heterogeneity are clearly described.
Subgroup analysis
performed/stated?
Uncertainty Sensitivity analyses are performed on
parameter source uncertainty (deterministic),
parameter precision (probabilistic), and
analysis structure (structural).
Structural sensitivity
analysis performed?
Magnitude of uncertainty in the model’s
structure, parameters, and precision are
reported.
Reported results of
sensitivity analysis?
Sensitivity analysis of
parameter source
performed (deterministic)?
Sensitivity analysis of
parameter precision
performed (probabilistic)?
Budget impact Intervention(s) budget impact is assessed. Budget impact assessment
performed?
Intervention(s) budget impact is
reported.
Impact on budget
stated?
Equity
considerations
Intervention(s) implications on equity are
assessed.
Equity addressed at all in
the paper?
Intervention(s) implications on equity are
stated.
Influence of equity
considerations stated in
the paper?
DALY: disability-adjusted life year; QALY: Quality-adjusted life year; LY: life year; USD: United States dollar; ICER: incremental cost-effectiveness ratio.
Evaluation questions scored as either 0 (item not satisfied) or 1 (item satisfied), and are each weighted equally. Optional requirements noted in Table A in S1 File and
are only included in sensitivity analysis scoring.
https://doi.org/10.1371/journal.pone.0205633.t001
CEA adherence to the iDSI reference case
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Statistical analysis. To examine whether the iDSI guideline has, since its release in 2014,
improved the methodological and reporting practices of cost-per-DALY averted studies, we
calculated mean adherence scores by year from 2011 to 2017. We conducted a pre-post analy-
sis of improvement in methodological and reporting adherence scores. As the reference case
was first released in January of 2014 [21], we considered that year to be the reference case’s dis-
semination period, and hence did not include articles published during that year in our pre-
post analysis. We also compared the overall methodological and reporting adherence scores,
stratified by the 11 principles.
Sensitivity analysis. We conducted three sensitivity analyses. First, we included the
“optional” criteria in the calculation of adherence scores for a random 10% subset of the arti-
cles to explore the impact of including optional items in the adherence score. Second, given
that efforts to increase awareness of new guidelines may take longer than one year, and subse-
quent development and publication of adherent CEAs can span more time, we conducted a
sensitivity analysis to explore alternate dissemination period lengths. Primarily, we expanded
the dissemination period from 2014 to 2014–2015 to examine the influence of a longer dissem-
ination period on adherence. Third, we used an alternative classification to determine adher-
ence to the comparator principle’s corresponding methodological specification. In our base
case analysis, we designated an article adherent to the iDSI’s comparator methodological speci-
fication only if the article explicitly reported their comparator as the “standard of care”. In this
sensitivity analysis, we classified an article as adherent so long as it specified a comparator
other than “do nothing” or some other non-action. To be consistent with the iDSI reference
case principle that the standard of care must include at least “minimal supportive care” [22],
we designated “do-nothing” interventions as non-adherent.
Results
Descriptive statistics
Among 398 cost-per-DALY averted studies published from 2011–2017, 215 (54%) focused on
LMICs and 263 (68%) targeted communicable diseases, such as diarrhea, HIV/AIDs, tubercu-
losis, and malaria (Table 2). Articles averaged 60% adherence to the reference case’s methodo-
logical specifications and 74% adherence to reporting standards. Table 3 summarized iDSI
Reference case normalized adherence scores by year, sponsor, and journal aspects (The raw
scores are available from Table B in S1 File). No article achieved full adherence to either the
methodological specifications or the reporting standards.
Of the 213 articles published after 2014 (i.e. 2015–2017), only 9 (4%) cited the iDSI refer-
ence case. For articles that did so, adherence to reporting standards averaged 79%, five per-
centage points higher than mean adherence for the full sample, while adherence to
methodological specifications did not differ from adherence for the full sample. Funding
source (BMGF vs. non-BMGF) was not significantly associated with a change in adherence
scores for either methodological (mean score of 60% vs. 60%) or reporting (mean score of 75%
vs. 74%).
Studies published in clinical journals had marginally higher adherence (60% methodologi-
cal adherence, 74% reporting adherence) than studies in non-clinical journals (57% methodo-
logical adherence, 73% reporting adherence). On average, methodological adherence scores
for articles published in high-impact journals exceeded the corresponding scores for studies
published in low-impact journals (61% vs. 50%); for reporting adherence, the corresponding
difference was 74% vs. 71%.
Methodological adherence did not improve after publication of the reference case com-
pared to the pre-2014 period (59% adherence pre-2014 vs. 60% post-2014, p = 0.53). Reporting
CEA adherence to the iDSI reference case
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standard adherence slightly increased (72% adherence pre-2014 vs. 75% post-2014, p<0.01)
(Fig 1 and Table C in S1 File).
Table 2. Characteristics of cost-per-DALY averted studies published 2011–2017.
GBD Super Region Number of studies % of the sample
Sub-Saharan Africa 125 31.4
High Income 66 17.0
Multiple Regions # 52 13.1
Southeast Asia, East Asia, and Oceania 45 11.6
South Asia 36 9.3
Latin America and Caribbean 33 8.5
N/A 22 5.7
North Africa and Middle East 10 2.6
Central Europe, Eastern Europe, and Central Asia 9 2.3
Intervention�
Pharmaceutical 112 28.1
Immunization 106 26.6
Care delivery 74 18.6
Health education or behavior 73 18.3
Screening 63 15.8
Surgery 36 9.1
Other 34 8.5
Medical procedure 15 3.8
GBD Disease Category
Other 90 22.6
Diarrhea, LRI, and other common infectious diseases 79 21.1
HIV/AIDS and tuberculosis 79 21.1
Neglected tropical diseases and malaria 41 11.0
Mental and behavioral disorders 28 7.5
Other communicable, maternal, neonatal, and
nutritional disorders
25 6.7
Cardiovascular and circulatory disease 24 6.4
Diabetes, urogenital, blood, and endocrine disorders 16 4.3
Neoplasms 12 3.2
Digestive diseases 4 1.1
Study sponsor�
Government 153 38.4
Foundation 124 31.2
Academics 53 13.3
Intergovernmental Org 41 10.3
Other 24 6.0
Healthcare Org^ 23 5.8
Industry 16 4.0
# “Multiple regions”: studies that reported cost-effectiveness estimates for countries in different regions.
� Not mutually exclusive. GBD: Global burden of disease.
^ Health care organizations include insurance companies, hospitals. LRI: Lower respiratory infection.
Source: Tufts Medical Center Global Health Cost-Effectiveness Registry (www.ghcearegistry.org)
https://doi.org/10.1371/journal.pone.0205633.t002
CEA adherence to the iDSI reference case
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Table 3. iDSI reference case adherence scores by year, sponsor, and journal aspects.
Methodological adherence: Normalized score
(out of 100)
Reporting adherence:
Normalized score
(out of 100)
N Mean (SD) Min Max Mean (SD) Min Max
Base case analysis 398 59.6 (11.5) 26.3 89.5 73.9 (8.5) 42.9 90.5
Pre-post period1
Pre-period: 2011–2013 138 58.9 (12) 26.3 89.5 72.3 (9.1)� 42.9 90.5
Post-period: 2015–2017 213 59.7 (11.4) 26.3 89.5 74.9 (7.9)� 47.6 90.5
Study sponsor2
Academic 53 59.7 (12.7) 36.8 84.2 75 (8.2) 52.4 90.5
Government 153 60.7 (11) 31.6 89.5 75.4 (7.5) 47.6 90.5
Healthcare Org 23 65.4 (11) 31.6 89.5 77.2 (8.1) 57.1 90.5
Industry 16 60.5 (11.2) 31.6 73.7 74.7 (7.3) 57.1 90.5
Intergovernmental 41 61.9 (10.3) 36.8 84.2 74.4 (7.6) 61.9 90.5
Foundation 56 60.2 (12) 36.8 89.5 74.1 (8.2) 57.1 90.5
BMGF 74 60.1 (11) 31.6 84.2 75.4 (8.5) 47.6 90.5
Other 24 58.6 (13.5) 31.6 84.2 73.2 (8.9) 52.4 90.5
Cite reference case
Yes 9 62.0 (12.6) 47.4 89.5 78.8 (7.6) 71.4 90.5
No 251 59.9 (11.2) 26.3 84.2 74.5 (8.0) 47.6 90.5
Journal type
Clinical 318 60.3 (11)� 26.3 89.5 74.2 (7.9) 47.6 90.5
Non-clinical 80 56.8 (13.1)� 26.3 78.9 72.5 (10.2) 42.9 90.5
Journal impact factor3
High 336 60.5 (11.2)� 26.3 89.5 74.1 (8.6) 42.9 90.5
Medium 45 56.1 (12.7) 26.3 73.7 73 (7.5) 57.1 90.5
Low 12 50 (6.9)� 42.1 63.2 70.6 (9.7) 52.4 85.7
Sensitivity analyses
#1: Inclusion of "optional” elements
Base case analysis 398 59.6 (11.5) 26.3 89.5 73.9 (8.5) 42.9 90.5
10% random sample4 40 46.2 (8.3) 23.3 66.7 52.4 (5.6) 39.4 63.2
#2: Alternate dissemination period
Pre-period: 2011–2013 138 58.9 (12) 26.3 89.5 72.3 (9.1) 42.9 90.5
Post-period: 2016–2017 135 59.2 (11.6) 26.3 84.2 74.6 (7.4) 57.1 90.5
#3: Alternate comparator classification5
Base case: standard of care 398 59.6 (11.5) 26.3 89.5 N/A
Use of any comparator 398 60.4 (11.7) 26.3 89.5 N/A
�: Statistically significant difference (p<0.05) between categories (within methods/reporting requirements) per Student’s t-test
1: Year 2014 was excluded from pre-post analysis to serve as dissemination period.
2: Categories are not mutually exclusive, t-test not calculated.
3: Journal impact factor categories defined by 2016 SCImago Journal Rank quartile: high = first quartile; medium = second quartile; low = third and fourth quartiles.
Five journals’ impact factors were not available.
4: Base case scoring only included reference case elements designated as “required” per report language. “Optional” elements reintroduced in sensitivity analysis of
random subsample of 10% of articles.
5: Any listed comparator scored as adherent, unless comparator was “do-nothing”.
https://doi.org/10.1371/journal.pone.0205633.t003
CEA adherence to the iDSI reference case
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Methodological adherence versus reporting adherence scores
Across the 11 principles, reporting standard adherence exceeded methodological specification
adherence by 14 percentage points (74% vs. 60%). Reporting adherence score were highest for
the following principles: uncertainty (mean of 100%), comparator (97%), and evidence (95%).
Methodological adherence scores were highest for the outcome measure (100%), transparency
(89%), and evidence (74%) principles (Fig 2).
Methodological adherence scores were higher than reporting adherence scores for the fol-
lowing principles: transparency (89% methodological adherence score vs. 86% reporting
adherence score), outcome (100% vs. 54%), and costs (65% vs. 54%). Reporting adherence
scores exceeded methodological adherence scores for the following principles: comparator
(36% methodological adherence score vs. 97% reporting adherence score), evidence (74% vs.
95%), time horizon/discounting (57% vs. 82%), perspective (64% vs. 85%), and uncertainty
(57% vs. 100%) (Fig 2). Articles seldom addressed the principles of budget impact (10% meth-
odological adherence score, 9% reporting) or equity (7%, 7%) (Fig 2).
Sensitivity analyses
Inclusion of optional criteria in our adherence score calculation decreased mean methodologi-
cal adherence by 14 percentage points (60% to 46%) and mean reporting adherence by 22 per-
centage points (from 74% to 52%). When we increased the dissemination period to 2014–2015
(base case: 2014), we found no change in our results. Using an alternate comparator principle
classification (base case: comparator must be standard of care; alternative: comparator can be
any intervention other than “do-nothing”) also had little impact.
Fig 1. iDSI reference case adherence scores and number of cost-per-DALY averted studies over time.
https://doi.org/10.1371/journal.pone.0205633.g001
CEA adherence to the iDSI reference case
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Discussion
Since its introduction in 2014, adherence to the iDSI reference case among published cost-per-
DALY averted studies has improved for reporting standards, but not for methodological speci-
fications. Adherence to the reference case’s reporting standards exceeds adherence to its meth-
odological specifications, perhaps reflecting the relative ease of revising the way information is
presented and greater effort needed to conform to analytic requirements. Moreover, other
reporting guidelines, such as CHEERS [7] or country-specific recommendations, may have
independently promoted more rigorous reporting, with the unintended effect of boosting
adherence to the iDSI reference case.
However, methodological and reporting adherence scores varied substantially across refer-
ence case principles, demonstrating ways in which articles are falling short of guidelines. For
example, articles almost always report their comparator clearly (as recommended by reporting
standards), but do not necessarily specify whether the comparator is considered standard of
care (as recommended by methodological specifications). Similarly, all articles reported find-
ings from sensitivity analyses, but did not always conduct comprehensive structural, probabi-
listic, and deterministic sensitivity analyses.
In some cases, methodological adherence exceeded reporting adherence. For example, arti-
cles often included implementation costs (as recommended by methodological specifications),
but did not as frequently report these costs in both US dollars and local currency (as recom-
mended by reporting standards). Because the methodological specifications and reporting
Fig 2. Methodological vs. reporting adherence scores: Overall and by each principle.
https://doi.org/10.1371/journal.pone.0205633.g002
CEA adherence to the iDSI reference case
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standards address distinct issues, future guidelines should continue to include recommenda-
tions for both types.
It is important to consider what level of adherence should be seen as satisfactory. Although
articles in our sample were more adherent to reporting guidelines, they adhered to just over
half of methodological specifications. Adherence scores were notably lower for particular prin-
ciples—heterogeneity, budget impact, and equity—indicating overall neglect of these issues in
cost-per-DALY averted studies. The adherence scores are perhaps best thought of as a baseline
against which to measure improvement, and as a call to action to promote higher quality and
comparability.
The lack of adherence to the iDSI reference case might reflect the competing influences of
other guidelines, as authors may prioritize adherence to local guidelines that are more relevant
to their context [3, 11]. For example, the South African pharmacoeconomic guidelines recom-
mend a base case 5% discount rate, which differs from the 3% value recommended by the ref-
erence case [23]. Although the iDSI reference case supports the use of alternative discount
rates where appropriate to the decision problem and constituency, published CEAs that adhere
to the local guidelines may be scored as non-adherent to the methodological specifications in
this analysis.
Another possible explanation for relatively low adherence for certain items is that authors
may not be aware of the guidelines. We found that only 4% of the identified studies published
after 2014 directly cited the iDSI reference case. The BMGF and iDSI have focused educational
campaigns on national payers and health technology assessment (HTA) agencies in LMICs,
rather than on researchers, who are primary authors of published studies [22]. Future studies
should examine whether the reference case has influenced country-specific guidelines, such as
Thailand’s HTA assessment guideline [9].
Limitations
The primary limitation of our study is that the post-evaluation period (2015–2017) may not
have been sufficiently long to detect the impact of the reference case. Though it was initially
released in early 2014, as noted, the iDSI reference case was not officially published in an aca-
demic journal until 2016 [16]. However, dissemination efforts began in 2013 at a BMGF-
hosted workshop for multi-sectoral stakeholders, which was later considered “a major part of
the Gates reference case development”[14]. Although more time may be needed for the field to
adopt these guidelines, as new CEAs can take years to conduct and publish, we believe our
results on adherence to the iDSI reference case can serve as a baseline estimate. Adherence
should be re-analyzed in the future as the field continues to grow.
Furthermore, our use of dichotomous (i.e., “yes/no”) questions to score adherence may be
inconsistent with the more nuanced goals of the iDSI reference case. Because the reference
case is designed to be applicable in a range of different country-specific contexts, it must bal-
ance the goals of study comparability and quality against the goal of local applicability [6, 22,
24]. To address this limitation, we omitted “optional” standards from our adherence calcula-
tion for the base case. That is, we assumed that the “optional” elements represent conditional
requirements intended by the reference case authors to allow for local adaptability. Our sensi-
tivity analysis that included all elements in our calculation of the adherence score (i.e. both the
“required” and “optional” elements) yielded lower adherence scores.
Assessing adherence to the comparator principle posed a particular challenge because this
assessment requires subjective judgment on whether the specified comparator constitutes the
“standard of care.” Although our sensitivity analysis of altering the definition of appropriate
comparator had little impact on our findings, a “do nothing” intervention, which is deemed
CEA adherence to the iDSI reference case
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inappropriate by the iDSI’s comparator methodological specification, can be regarded as “stan-
dard of care” for some conditions in some settings, such as a population screening program
for tuberculosis [25, 26].
Also, our findings cannot be generalized to the rest of the economic evaluation literature as
the Tufts Medical Center Global Health CEA Registry catalogs only published cost-per-DALY
averted studies. For example, our analysis excluded gray literature (i.e., material not dissemi-
nated in regularly published, indexed journals). Gray literature may be more prevalent in
some countries, especially those without local guidelines.
Finally, our approach for scoring articles inherently involves reviewer judgment to deter-
mine author intent and to resolve ambiguities (e.g., determining whether the comparator is
“clearly” stated). We attempted to mitigate this problem by having two reviewers read each
article and, in cases of no consensus, we appealed to a third reviewer.
Policy implications
As posited by Nugent and Briggs, future research on the subject should ask, “what specific help
does the iDSI reference case offer the analyst, who, while attempting to conform to the princi-
ples, nevertheless has to choose and implement the methods?” [27] It is possible that the meth-
odological guidelines impose an excessive burden on researchers, raising “issues about the
resources and data requirements to meet the principles” [22].
Future qualitative research can focus on researcher consideration of best practice guidelines
in study design and reporting, and on how to increase guideline acceptance among authors.
Studies could also further evaluate the methods and reporting adherence for articles that
strongly adhere to the iDSI reference case, as these analyses may serve as useful examples for
other CEA authors. Analysis of the impact of the reference case on perceived quality and use-
fulness of economic evaluations by decision makers would be useful.
Moving from guideline development to implementation is a vital step towards improving
the quality of economic evidence in global health. Future efforts could include additional edu-
cational workshops for researchers, students, and policymakers. Policymakers and major
funders of economic evaluations, such as the BMGF, could require that researchers adhere to
reference case recommendations in grant applications. Journals and reviewers should also
impose high-quality standards for economic evaluations. Moving forward, journals may
require reviewers to fill out a rubric similar to the instrument in our study that measures the
adherence of economic evaluations to the iDSI reference case guidelines.
Conclusion
Since its initial launch in 2014, our study indicates that the development of the iDSI reference
case is associated with improving reporting standards for economic evaluation focused on
global health, but no improvement in methodological practice. Although the reference case
has substantial potential to serve as a resource for researchers and policy makers in global
health and economics, more effort to promote adherence and awareness may be needed.
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